Lentitek: Biotech Firm Secures £1m Funding to Advance Cancer Treatments
Deal News | Mar 05, 2025 | Scottish Enterprise
Lentitek, a biotech company based in Edinburgh, Scotland, has successfully raised a total of £1 million to further its research into next-generation cancer treatments. Out of this total, £700,000 was contributed by Equity Gap, a prominent angel investment syndicate in Scotland. The remaining funds likely stemmed from other sources connected to Scottish Enterprise, though details were not provided. This funding injection reflects the confidence investors have in Lentitek's cutting-edge oncology solutions and their potential impact on cancer treatment advancements.
Sectors
- Biotechnology
- Healthcare Investments
Geography
- Scotland – Lentitek is based in Edinburgh, and the funding includes significant involvement from the Scottish angel investment syndicate, Equity Gap.
Industry
- Biotechnology – The article discusses Lentitek, a biotech company that focuses on the development of next-generation treatments for cancer.
- Healthcare Investments – The article involves funding activities by private investors and syndicates to support healthcare innovations, particularly in cancer treatment.
Financials
- £1,000,000 – Total funding secured by Lentitek over the past six months.
- £700,000 – Amount invested by Equity Gap, a Scottish angel investment syndicate.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Lentitek Ltd | Target Company | Company | A biotech company based in Edinburgh, engaged in developing next-generation cancer treatments. |
| Equity Gap | Investor | Company | A Scottish angel investment syndicate that contributed £700,000 in funding. |
| Scottish Enterprise | PE Firm | Company | Associated with the funding process for Lentitek to support its advancements in cancer treatment. |